tradingkey.logo


IQVIA Holdings Inc

IQV

191.540USD

-3.010-1.55%
āļ›āļīāļ” 07/30, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
32.56BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
24.41P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ IQVIA Holdings Inc āļšāļĢāļīāļĐāļąāļ—
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™IQV
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—IQVIA Holdings Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļMay 09, 2013
āļāđˆāļ­āļ•āļąāđ‰āļ‡āđ€āļĄāļ·āđˆāļ­2016
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Ari Bousbib
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™88000
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“May 09
āļ—āļĩāđˆāļ­āļĒāļđāđˆ2400 Ellis Road
āđ€āļĄāļ·āļ­āļ‡DURHAM
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNYSE Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ27703
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ19199982000
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://ir.iqvia.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™IQV
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļMay 09, 2013
āļāđˆāļ­āļ•āļąāđ‰āļ‡āđ€āļĄāļ·āđˆāļ­2016
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Ari Bousbib
Mr. Ari Bousbib
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.35M
+0.75%
Mr. Ronald E. (Ron) Bruehlman
Mr. Ronald E. (Ron) Bruehlman
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
46.46K
-1.91%
Mr. John G. Danhakl
Mr. John G. Danhakl
Independent Director
Independent Director
30.85K
-79.16%
Mr. Eric M. Sherbet
Mr. Eric M. Sherbet
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
21.11K
--
Ms. Colleen A. Goggins
Ms. Colleen A. Goggins
Independent Director
Independent Director
16.83K
+10.45%
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
Lead Independent Director
Lead Independent Director
15.38K
+11.55%
Ms. Carol J. Burt
Ms. Carol J. Burt
Independent Director
Independent Director
7.01K
+17.56%
Mr. James A. Fasano
Mr. James A. Fasano
Independent Director
Independent Director
2.74K
+157.67%
Mr. John P. Connaughton
Mr. John P. Connaughton
Independent Director
Independent Director
1.05K
--
Mr. Bhavik Patel
Mr. Bhavik Patel
President, Commercial Solutions
President, Commercial Solutions
947.00
-10.24%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Ari Bousbib
Mr. Ari Bousbib
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.35M
+0.75%
Mr. Ronald E. (Ron) Bruehlman
Mr. Ronald E. (Ron) Bruehlman
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
46.46K
-1.91%
Mr. John G. Danhakl
Mr. John G. Danhakl
Independent Director
Independent Director
30.85K
-79.16%
Mr. Eric M. Sherbet
Mr. Eric M. Sherbet
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
21.11K
--
Ms. Colleen A. Goggins
Ms. Colleen A. Goggins
Independent Director
Independent Director
16.83K
+10.45%
Dr. John M. Leonard, M.D.
Dr. John M. Leonard, M.D.
Lead Independent Director
Lead Independent Director
15.38K
+11.55%
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Americas
1.81B
47.19%
Europe & Africa Region
1.22B
31.97%
Asia Pacific Region
798.00M
20.84%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 24 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 24 āļ.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
11.62%
Harris Associates L.P.
6.57%
BlackRock Institutional Trust Company, N.A.
5.81%
State Street Global Advisors (US)
4.54%
GIC Private Limited
3.85%
Other
67.60%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
The Vanguard Group, Inc.
11.62%
Harris Associates L.P.
6.57%
BlackRock Institutional Trust Company, N.A.
5.81%
State Street Global Advisors (US)
4.54%
GIC Private Limited
3.85%
Other
67.60%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
45.65%
Investment Advisor/Hedge Fund
31.75%
Hedge Fund
6.56%
Sovereign Wealth Fund
4.94%
Pension Fund
4.66%
Research Firm
2.37%
Bank and Trust
2.16%
Individual Investor
0.91%
Family Office
0.10%
Other
0.90%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
2018
167.15M
96.62%
-8.83M
2025Q1
2083
168.53M
97.38%
-9.36M
2024Q4
2059
171.87M
97.45%
+3.00M
2024Q3
2008
173.01M
95.44%
+863.78K
2024Q2
1977
164.85M
90.43%
-7.68M
2024Q1
1950
165.50M
90.84%
-10.38M
2023Q4
1948
168.90M
93.03%
-6.38M
2023Q3
1925
170.01M
92.82%
-4.41M
2023Q2
1898
167.84M
91.62%
-8.26M
2023Q1
1870
169.28M
91.24%
-7.20M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
The Vanguard Group, Inc.
19.76M
11.42%
-293.38K
-1.46%
Mar 31, 2025
Harris Associates L.P.
11.17M
6.46%
-166.29K
-1.47%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.88M
5.71%
-196.58K
-1.95%
Mar 31, 2025
State Street Global Advisors (US)
7.72M
4.46%
-157.55K
-2.00%
Mar 31, 2025
GIC Private Limited
6.54M
3.78%
-2.59M
-28.36%
Mar 31, 2025
CPP Investment Board
4.59M
2.66%
+312.81K
+7.31%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.24M
2.45%
+59.53K
+1.43%
Mar 31, 2025
AllianceBernstein L.P.
3.54M
2.04%
-57.68K
-1.60%
Mar 31, 2025
Farallon Capital Management, L.L.C.
3.41M
1.97%
+288.70K
+9.24%
Mar 31, 2025
Capital Research Global Investors
2.13M
1.23%
+589.82K
+38.40%
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
First Trust Nasdaq Lux Digi Health Solutions ETF
6.05%
VanEck Biotech ETF
3.83%
Global X HealthTech ETF
3.58%
Langar Global HealthTech ETF
2.7%
iShares Biotechnology ETF
2.58%
American Century Focused Large Cap Value ETF
2.11%
American Century Mid Cap Growth Impact ETF
2.05%
Running Oak Efficient Growth ETF
1.7%
Invesco Zacks Mid-Cap ETF
1.59%
Fidelity Digital Health ETF
1.52%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
First Trust Nasdaq Lux Digi Health Solutions ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™6.05%
VanEck Biotech ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.83%
Global X HealthTech ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.58%
Langar Global HealthTech ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.7%
iShares Biotechnology ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.58%
American Century Focused Large Cap Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.11%
American Century Mid Cap Growth Impact ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.05%
Running Oak Efficient Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.7%
Invesco Zacks Mid-Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.59%
Fidelity Digital Health ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.52%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™